Cesar Sanchez

Cesar Sanchez

Auto-generated profile, based on publicly available information

Cesar Sanchez

Laboratorio de Biotecnología y Biología Molecular, Instituto Nacional de Salud, Lima 15046, Peru

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MMMartin Montes
Martin Montes
CSCesar Sanchez
Cesar Sanchez
KVKristien Verdonck
Kristien Verdonck
JLJordan E. Lake
Jordan E. Lake
EGElsa Gonzalez
Elsa Gonzalez
AWA. Clinton White
A. Clinton White
Human strongyloidiasis varies from a chronic but limited infection in normal hosts to hyperinfection in patients treated with corticosteroids or with HTLV-1 co-infection. Regulatory T cells dampen immune responses to infections. How human strongyloidiasis is controlled and how HTLV-1 infection affects this control are not clear. We hypothesize that HTLV-1 leads to dissemination of Strongyloides stercoralis infection by augmenting regulatory T cell numbers, which in turn down regulate the immune response to the parasite. To measure peripheral blood T regulatory cells and Strongyloides stercoralis larval antigen-specific cytokine responses in strongyloidiasis patients with or without HTLV-1 co-infection. Peripheral blood mononuclear cells (PBMCs) were isolated from newly diagnosed strongyloidiasis patients with or without HTLV-1 co-infection. Regulatory T cells were characterized by flow cytometry using intracellular staining for CD4, CD25 and FoxP3. PBMCs were also cultured with and without Strongyloides larval antigens. Supernatants were analyzed for IL-5 production. Patients with HTLV-1 and Strongyloides co-infection had higher parasite burdens. Eosinophil counts were decreased in the HTLV-1 and Strongyloides co-infected subjects compared to strongyloidiasis-only patients (70.0 vs. 502.5 cells/mm3, p = 0.09, Mann-Whitney test). The proportion of regulatory T cells was increased in HTLV-1 positive subjects co-infected with strongyloidiasis compared to patients with only strongyloidiasis or asymptomatic HTLV-1 carriers (median = 17.9% vs. 4.3% vs. 5.9 p<0.05, One-way ANOVA). Strongyloides antigen-specific IL-5 responses were reduced in strongyloidiasis/HTLV-1 co-infected patients (5.0 vs. 187.5 pg/ml, p = 0.03, Mann-Whitney test). Reduced IL-5 responses and eosinophil counts were inversely correlated to the number of CD4+CD25+FoxP3+ cells. Regulatory T cell counts are increased in patients with HTLV-1 and Strongyloides stercoralis co-infection and correlate with both low circulating eosinophil counts and reduced antigen-driven IL-5 production. These findings suggest a role for regulatory T cells in susceptibility to Strongyloides hyperinfection. Human strongyloidiasis varies from a mild, controlled infection to a severe frequently fatal disseminated infection depending on the hosts. Patients infected with the retrovirus HTLV-1 have more frequent and more severe forms of strongyloidiasis. It is not clear how human strongyloidiasis is controlled by the immune system and how HTLV-1 infection affects this control. We hypothesize that HTLV-1 leads to dissemination of Strongyloides stercoralis by augmenting regulatory T cell numbers, which in turn down regulate the immune response to the parasite. In our study, patients with HTLV-1 and Strongyloides co-infection had higher parasite burdens than patients with only strongyloidiasis. Eosinophils play an essential role in control of strongyloidiasis in animal models, and eosinophil counts were decreased in the HTLV-1 and Strongyloides stercoralis co-infected subjects compared to patients with only strongyloidiasis. The proportion of T cells with a regulatory cell phenotype was increased in HTLV-1 positive subjects co-infected with strongyloidiasis compared to patients with only strongyloidiasis. IL-5 is a key host molecule in stimulating eosinophil production and activation, and Strongyloides stercoralis antigen-specific IL-5 responses were reduced in strongyloidiasis/HTLV-1 co-infected patients. Reduced IL-5 responses and eosinophil counts were inversely correlated to the number of regulatory T cells. These findings suggest a role for regulatory T cells in susceptibility to Strongyloides hyperinfection.

1 August 2006 in AIDS
Verified
Journal Article
Closed access
MMMartin Montes
Martin Montes
DLDorothy E Lewis
Dorothy E Lewis
CSCesar Sanchez
Cesar Sanchez
DCDiego Lopez de Castilla
Diego Lopez de Castilla
EGEdward A Graviss
Edward A Graviss
AWA. Clinton White
A. Clinton White
We characterized regulatory T cells from antiretroviral-naive HIV patients by flow cytometry. The proportion of CD4 cells positive for CD25 and Foxp3 was increased, mainly in those with CD4 cell counts less than 200 cells/microl. The total number of Foxp3-positive cells correlated with the CD4 cell count. Further studies are needed on whether Foxp3-positive cell numbers or function explain the susceptibility to autoimmune and inflammatory diseases seen in some patients with advanced HIV.

20 September 2011 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
SSSebastian Sattui
Sebastian Sattui
CFCarolina de la Flor
Carolina de la Flor
CSCesar Sanchez
Cesar Sanchez
DLDorothy Lewis
Dorothy Lewis
GLGiovanni Lopez
Giovanni Lopez
MMMartin Montes
Martin Montes

21 December 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MMMartin Montes
Martin Montes
CSCesar Sanchez
Cesar Sanchez
DLDorothy E. Lewis
Dorothy E. Lewis
EGEdward A. Graviss
Edward A. Graviss
CSCarlos Seas
Carlos Seas
AWA. Clinton White
A. Clinton White
Regulatory T cells (Tregs) blunt uncontrolled immune responses. In advanced human immunodeficiency virus (HIV) infection, the total number of Tregs is decreased, but the proportion of T cells with a regulatory phenotype is highly variable. We studied CD4+CD25+FoxP3+ T cells from patients successfully treated with combination antiretroviral therapy (ART). The proportion of CD4+CD25+FoxP3+ cells transiently increased and then decreased from a median of 13% at baseline to 5.1% at 48 weeks, similar to values in normal subjects. These data suggest that with effective therapy, the regulatory cell numbers normalize, and that the inflammatory signals driving their production may also abate.

1 November 2018 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
HGHEINNER GUIO
HEINNER GUIO
JPJulio A. Poterico
Julio A. Poterico
KLKelly S Levano
Kelly S Levano
Mario Cornejo-OlivasMario Cornejo-Olivas
Mario Cornejo-Olivas
PMPilar Mazzetti
Pilar Mazzetti
HAHugo Hernán Abarca-Barriga
Hugo Hernán Abarca-Barriga
Peruvians currently preserve in their DNA the history of 2.5 million years of human evolution and 150,000 years of migration from Africa to Peru or the Americas. The development of Genetics and Genomics in the clinical and academic field is shown in this review.

24 June 2022 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
LJLuis Jose Jaramillo-Valverde
Luis Jose Jaramillo-Valverde
KLKelly S Levano
Kelly S Levano
DTDavid Tarazona
David Tarazona
SCSilvia Capristano
Silvia Capristano
Roberto Zegarra-ChapoñanRoberto Zegarra-Chapoñan
Roberto Zegarra-Chapoñan
HGHEINNER GUIO
HEINNER GUIO
Background: In Peru, 32,970 people were diagnosed with tuberculosis (TB) in 2019. Although TB treatment is effective, 3.4%–13% is associated with significant adverse drug reactions (ADR), considering drug‐induced liver injury (DILI) as the most prevalent. Among the first‐line anti‐TB drugs, isoniazid (INH) is primarily responsible for the occurrence of DILI. INH is metabolized in the liver by the enzymes N‐acetyltransferase‐2 (NAT2) and Cytochrome P450 2E1 (CYP2E1). Based on the previous studies, we hypothesized that the interactions between slow CYP2E1 genotype and NAT2 slow acetylators will induce DILI in TB patients.Methods: In this cross‐sectional study, all 377 participants completed their anti‐TB treatment, and we genotyped SNPs: rs1041983, rs1801280, rs1799929, rs1799930, rs1208, and rs1799931 for NAT2 and rs3813867 and rs2031920 for CYP2E1.Results: We found that rapid, intermediate, and slow NAT2 acetylator were 15%, 38%, and 47%, respectively, in the general population. Intermediate NAT2 acetylator is the least prevalent among patients with adverse reactions (p = 0.024). We did not confirm our hypothesis, however, we found that the combination of intermediate NAT2 acetylators and CYP2E1 c1/c1 genotype significantly protected (OR = 0.16; p = 0.049) against the development of DILI in our population.Conclusion: We propose that the presence of NAT2 intermediate and CYP2E1 c1/c1 genotype could help in therapeutic drug monitoring, and optimize its therapeutic benefits while minimizing its risk for side effects or toxicity.